A Blood-Based Test for Colorectal Cancer Screening

Area of Science:

• Oncology
• Genetics
• Public Health

Background:

• Colorectal cancer (CRC) is a leading cause of cancer death in the US, with screening rates below national targets.
• Current screening methods have limitations, and non-invasive options are needed to improve adherence.
• The National Colorectal Cancer Roundtable aims for 80% CRC screening, a target not yet met in the US.

Purpose of the Study:

• To review the FDA-approved Shield blood-based DNA test for colorectal cancer (CRC) screening.
• To analyze the ECLIPSE trial results, which supported the FDA approval of Shield.
• To evaluate the potential benefits, risks, and cost-effectiveness of implementing Shield in routine clinical practice.

Main Methods:

• PubMed search for "blood-based colorectal cancer screening" articles.
• Focus on studies related to the Shield test and its FDA approval.
• Synopsis of the ECLIPSE cohort trial data.

Main Results:

• The Shield test is the first blood-based DNA screening test for CRC approved by the US FDA.
• FDA approval was based on the large ECLIPSE cohort trial.
• The study provides data on the performance of Shield in a real-world setting.

Conclusions:

• Blood-based CRC screening tests like Shield have the potential to increase screening rates.
• Wider adoption of effective screening could lead to a reduction in CRC-related mortality.
• Further analysis of benefits, risks, and cost is crucial for clinical implementation.